HM
ANIK icon

HealthCor Management’s Anika Therapeutics ANIK Stock Holding History

HealthCor Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,540
Closed -$552K – 77
2021
Q1 		$552K Sell
13,540
-6,780
-33% -$257K 0.02% 81
2020
Q4 		$920K Buy
+20,320
New +$771K 0.04% 54

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HealthCor Management's ANIK Position: Q2 2021 in Review

HealthCor Management sold out of Anika Therapeutics (ANIK) in Q2 2021, closing a stake of 13,540 shares — an estimated $552K sold.

HealthCor Management first reported a position in ANIK in Q4 2020 and held it in 2 quarters. The position peaked at $920K in Q4 2020. 139 funds tracked by Wall St. Rank hold ANIK as of Q2 2021.

  • HealthCor Management reported no remaining Anika Therapeutics position as of Q2 2021 after selling out during the quarter.
  • HealthCor Management sold 13,540 Anika Therapeutics shares in Q2 2021, an estimated $552K.
  • HealthCor Management first reported a position in Anika Therapeutics in Q4 2020 and held it in 2 quarters.
  • HealthCor Management's Anika Therapeutics position peaked at $920K in Q4 2020.
  • 139 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2021.

Based on HealthCor Management's 13F filing for Q2 2021, filed 16 Aug 2021.